

May 13, 2008

APA DSM-V Work Group Member

Name, Degree: Perminder S. Sachdev M.D., Ph.D., FRANZCP

Role(s) in Work Group: Member, Neurocognitive Disorders Work Group

Institutional Affiliation(s): University of New South Wales

City, State: Sydney, NSW, Australia

Biographical Sketch:

Qualifications: MB BS (AIIMS) 1978, MD (Psychiatry) (AIIMS) 1981, FRANZCP 1985, PhD (Psychiatry) (UNSW) 1991, MFPOA 1995

Current positions: Professor of Neuropsychiatry, University of New South Wales 1999- & Clinical Director, Neuropsychiatric Institute, The Prince of Wales Hospital 1987-.

Professional roles: Immediate past-President, International Neuropsychiatric Association (INA) (2006-08); President, INA (2004-06); Chair, Neuropsychiatry Section, Royal Australian and New Zealand College of Psychiatrists; Convener, Neuropsychiatry Interest Group of NSW (1997-); Convener, Brain and Ageing Program, UNSW; Convener, 2008 annual meeting of the International College of Geriatric Psychoneuropharmacology; Honorary Medical Adviser and Founding Executive Member of Tourette Syndrome Association of Australia (1989-2002); Founding Member, International College of Geriatric Psychopharmacology; Convener, Biennial Congress of the International Neuropsychiatric Association, Sydney 2006; Vice-President of the Indo-Australasian Psychiatry Association 2004-06; Member of many professional societies and committees and editorial boards of journals. Referee for many international journals.

Research: Research in the areas of Vascular dementia, Alzheimer's disease, Dementia of Lewy Body type and other dementias, Neuropsychiatric aspects of dementia, including Depression; Treatment of resistant psychiatric disorders with Transcranial Magnetic Stimulation, Vagus Nerve Stimulation and Neurosurgery; Drug-induced movement disorders (akathisia, tardive dyskinesia, NMS); Neuroimaging; Tourette's syndrome, Adult ADHD. In 2008 developed a Neural Stem Cell Laboratory in the Faculties of Medicine and Science, UNSW. Awarded the Senior Research prize of the RANZCP in 1995 for most outstanding psychiatric research by an Aust or NZ psychiatrist in the preceding 2 years; Awarded the Novartis oration of the Australian Society for Psychiatric Research in 2004. Currently supervises 5 doctoral students, and co-supervises 3 doctoral students. Is the CI-A on a *Program Grant* (Sachdev/Brody/Andrews) awarded by the NH&MRC (2005-2009) for \$4.6 million for the investigation of neurocognitive disorders in the elderly; CI-A on a grant (\$2 million) to study elderly twins from the ARC/NHMRC Ageing Well Ageing Productively research program (2006-2011); and CI-B on a Primary Dementia Collaborative Research Centre grant (\$2.9 million over 3 years) awarded by Federal Department of Health and Ageing. CI-B on one ARC Discovery grant and one NHMRC Dementia Research Grant.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
Immediate Past-President, International Neuropsychiatric Association	2006-08	Serve on the executive committee
Neuropsychiatry Section, Royal Australian and New Zealand College of Psychiatrists	2007-2009	Chair
International College of Geriatric Psychoneuropharmacology	2007-1010	Board member
Tourette Syndrome Association of Australia	1989- 2008	Medical adviser
Society of Biological Psychiatry	1988 onwards	Member

The two tables below represent Dr. P. Sachdev's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Perminder Sachdev has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Pfizer Inc	2005, 2006	4 (Speaker's Bureau)
Astra Zeneca	2006, 2007	4 (Speaker's Bureau)
Wyeth	2006,2007	4 (Speaker's Bureau)
Novartis	2006	4 (Speaker's Bureau)
Lundbeck	2005, 2006	4 (Speaker's Bureau)
Eli Lilly	2005	4 (Speaker's Bureau)
Neuronetics	2005	3 (Investigator)

UPDATED 5.13.08

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
Astra Zeneca	2008	4 (Speaker's Bureau)
Orphan Australia	2008	4 (Speaker's Bureau)
Novartis	2008	4 (Speaker's Bureau)